SeaCrest Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

SeaCrest Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-92	Closed	-$2K	–	2163
2019 Q1	$2K	Hold	92	–	–	﹤0.01%	1979
2018 Q4	$2K	Hold	92	–	–	﹤0.01%	1961
2018 Q3	$2K	Sell	92 -92	-50%	-$1.75K	﹤0.01%	2117
2018 Q2	$3K	Hold	184	–	–	﹤0.01%	1968
2018 Q1	$3K	Hold	184	–	–	﹤0.01%	1945
2017 Q4	$3K	Buy	+184	New	+$2.58K	﹤0.01%	1964

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SeaCrest Wealth Management's HZNP Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2019, closing a stake of 92 shares — an estimated $2K sold.

SeaCrest Wealth Management first reported a position in HZNP in Q4 2017 and held it in 6 quarters. The position peaked at $3K in Q2 2018. 272 funds tracked by Wall St. Rank hold HZNP as of Q2 2019.

SeaCrest Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 92 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2019, an estimated $2K.
SeaCrest Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3K in Q2 2018.
272 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.